Catalyst Pharmaceuticals, Inc. (CPRX)
USD 21.34
(-7.52%)
USD 21.34
(-7.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 71.41 Million USD | -14.05% |
| 2022 | 83.07 Million USD | 110.42% |
| 2021 | 39.48 Million USD | -47.35% |
| 2020 | 74.98 Million USD | 135.24% |
| 2019 | 31.87 Million USD | 193.74% |
| 2018 | -34 Million USD | -84.68% |
| 2017 | -18.41 Million USD | -1.88% |
| 2016 | -18.07 Million USD | 10.68% |
| 2015 | -20.23 Million USD | -30.46% |
| 2014 | -15.5 Million USD | -27.6% |
| 2013 | -12.15 Million USD | -198.17% |
| 2012 | -4.07 Million USD | 36.22% |
| 2011 | -6.39 Million USD | -59.52% |
| 2010 | -4 Million USD | 44.68% |
| 2009 | -7.24 Million USD | 31.45% |
| 2008 | -10.56 Million USD | -155.21% |
| 2007 | -4.13 Million USD | -51.66% |
| 2006 | -2.72 Million USD | -51.18% |
| 2005 | -1.8 Million USD | -234.44% |
| 2004 | -539.82 Thousand USD | -25.95% |
| 2003 | -428.61 Thousand USD | -67.46% |
| 2002 | -255.94 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 40.79 Million USD | 75.27% |
| 2024 Q1 | 23.27 Million USD | -33.2% |
| 2023 Q4 | 34.84 Million USD | 213.26% |
| 2023 FY | 71.41 Million USD | -14.05% |
| 2023 Q2 | 37.76 Million USD | 27.71% |
| 2023 Q3 | -30.76 Million USD | -181.47% |
| 2023 Q1 | 29.56 Million USD | 16.08% |
| 2022 Q3 | 22.74 Million USD | 5.22% |
| 2022 Q4 | 25.47 Million USD | 11.97% |
| 2022 Q1 | 13.24 Million USD | 42.24% |
| 2022 Q2 | 21.61 Million USD | 63.27% |
| 2022 FY | 83.07 Million USD | 110.42% |
| 2021 Q2 | 12.18 Million USD | 58.96% |
| 2021 Q1 | 7.66 Million USD | -33.0% |
| 2021 Q4 | 9.3 Million USD | -9.88% |
| 2021 FY | 39.48 Million USD | -47.35% |
| 2021 Q3 | 10.32 Million USD | -15.2% |
| 2020 Q3 | 43.34 Million USD | 343.15% |
| 2020 Q1 | 10.42 Million USD | 31.48% |
| 2020 FY | 74.98 Million USD | 135.24% |
| 2020 Q2 | 9.78 Million USD | -6.2% |
| 2020 Q4 | 11.43 Million USD | -73.61% |
| 2019 Q3 | 13.63 Million USD | 24.36% |
| 2019 FY | 31.87 Million USD | 193.74% |
| 2019 Q1 | -644.5 Thousand USD | 95.56% |
| 2019 Q2 | 10.95 Million USD | 1800.53% |
| 2019 Q4 | 7.92 Million USD | -41.82% |
| 2018 Q2 | -5.96 Million USD | -4.65% |
| 2018 Q1 | -5.69 Million USD | -5.79% |
| 2018 FY | -34 Million USD | -84.68% |
| 2018 Q4 | -14.49 Million USD | -84.97% |
| 2018 Q3 | -7.83 Million USD | -31.41% |
| 2017 Q4 | -5.38 Million USD | -28.96% |
| 2017 FY | -18.41 Million USD | -1.88% |
| 2017 Q2 | -3.87 Million USD | 21.89% |
| 2017 Q1 | -4.96 Million USD | -19.31% |
| 2017 Q3 | -4.17 Million USD | -7.67% |
| 2016 Q4 | -4.16 Million USD | -5.29% |
| 2016 Q1 | -5.38 Million USD | 7.38% |
| 2016 Q3 | -3.95 Million USD | 13.46% |
| 2016 FY | -18.07 Million USD | 10.68% |
| 2016 Q2 | -4.56 Million USD | 15.17% |
| 2015 Q4 | -5.81 Million USD | -30.71% |
| 2015 Q1 | -5.41 Million USD | -55.02% |
| 2015 Q2 | -4.55 Million USD | 15.74% |
| 2015 FY | -20.23 Million USD | -30.46% |
| 2015 Q3 | -4.44 Million USD | 2.4% |
| 2014 Q2 | -3.19 Million USD | 16.09% |
| 2014 FY | -15.5 Million USD | -27.6% |
| 2014 Q4 | -3.49 Million USD | 30.34% |
| 2014 Q3 | -5 Million USD | -56.66% |
| 2014 Q1 | -3.81 Million USD | -181.33% |
| 2013 FY | -12.15 Million USD | -198.17% |
| 2013 Q1 | -1.74 Million USD | -2177.59% |
| 2013 Q2 | -3.14 Million USD | -80.22% |
| 2013 Q3 | -5.91 Million USD | -88.07% |
| 2013 Q4 | -1.35 Million USD | 77.09% |
| 2012 Q4 | -76.58 Thousand USD | 97.08% |
| 2012 Q1 | -1.08 Million USD | 53.69% |
| 2012 Q3 | -2.62 Million USD | -806.85% |
| 2012 FY | -4.07 Million USD | 36.22% |
| 2012 Q2 | -289.08 Thousand USD | 73.46% |
| 2011 Q4 | -2.35 Million USD | -108.53% |
| 2011 FY | -6.39 Million USD | -59.52% |
| 2011 Q2 | -1.39 Million USD | 8.11% |
| 2011 Q1 | -1.51 Million USD | -108.18% |
| 2011 Q3 | -1.12 Million USD | 19.1% |
| 2010 FY | -4 Million USD | 44.68% |
| 2010 Q3 | -903.98 Thousand USD | 31.96% |
| 2010 Q2 | -1.32 Million USD | -27.13% |
| 2010 Q1 | -1.04 Million USD | 10.07% |
| 2010 Q4 | -728.75 Thousand USD | 19.38% |
| 2009 Q2 | -1.76 Million USD | 41.87% |
| 2009 Q3 | -1.28 Million USD | 26.97% |
| 2009 Q4 | -1.16 Million USD | 9.68% |
| 2009 FY | -7.24 Million USD | 31.45% |
| 2009 Q1 | -3.03 Million USD | 19.12% |
| 2008 Q4 | -3.74 Million USD | -31.25% |
| 2008 Q3 | -2.85 Million USD | -20.1% |
| 2008 Q2 | -2.37 Million USD | -50.09% |
| 2008 Q1 | -1.58 Million USD | -67.64% |
| 2008 FY | -10.56 Million USD | -155.21% |
| 2007 FY | -4.13 Million USD | -51.66% |
| 2007 Q3 | -734.34 Thousand USD | 39.22% |
| 2007 Q4 | -944.93 Thousand USD | -28.68% |
| 2007 Q2 | -1.2 Million USD | 3.51% |
| 2007 Q1 | -1.25 Million USD | -68.92% |
| 2006 Q3 | -1.32 Million USD | -296.32% |
| 2006 Q2 | -333.41 Thousand USD | 0.0% |
| 2006 FY | -2.72 Million USD | -51.18% |
| 2006 Q1 | -333.41 Thousand USD | 74.77% |
| 2006 Q4 | -741.24 Thousand USD | 43.9% |
| 2005 Q3 | -241.85 Thousand USD | 63.4% |
| 2005 FY | -1.8 Million USD | -234.44% |
| 2005 Q4 | -1.32 Million USD | -446.48% |
| 2005 Q2 | -660.83 Thousand USD | 0.0% |
| 2005 Q1 | -660.83 Thousand USD | -389.67% |
| 2004 Q3 | -134.95 Thousand USD | 0.0% |
| 2004 Q2 | -134.95 Thousand USD | 0.0% |
| 2004 FY | -539.82 Thousand USD | -25.95% |
| 2004 Q1 | -134.95 Thousand USD | 0.0% |
| 2004 Q4 | -134.95 Thousand USD | 0.0% |
| 2003 FY | -428.61 Thousand USD | -67.46% |
| 2002 FY | -255.94 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 148.778% |
| Alkermes plc | 355.75 Million USD | 79.927% |
| Agenus Inc. | -245.76 Million USD | 129.057% |
| Aptorum Group Limited | -2.82 Million USD | 2628.104% |
| Ardelyx, Inc. | -66.06 Million USD | 208.087% |
| Dyadic International, Inc. | -6.79 Million USD | 1150.849% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 7729.274% |
| Lantern Pharma Inc. | -15.96 Million USD | 547.388% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 475.272% |
| Novavax, Inc. | -545.06 Million USD | 113.101% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 222.502% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 196.775% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 485.041% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 815.101% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 221.069% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 119.112% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 393.394% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 291.243% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 143.391% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 197.359% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 451.929% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 214.706% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 319.825% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 153.897% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 116.221% |
| AlloVir, Inc. | -190.41 Million USD | 137.502% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 134.787% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 350.984% |
| Bicycle Therapeutics plc | -180.66 Million USD | 139.526% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 139.882% |
| ChromaDex Corporation | -4.93 Million USD | 1546.132% |
| Chimerix, Inc. | -82.09 Million USD | 186.985% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 260.1% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 169.962% |
| CRISPR Therapeutics AG | -153.61 Million USD | 146.488% |
| Precision BioSciences, Inc. | -61.31 Million USD | 216.457% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 144.374% |
| Fortress Biotech, Inc. | -60.63 Million USD | 217.766% |
| Fortress Biotech, Inc. | -60.63 Million USD | 217.766% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 187.534% |
| ImmuCell Corporation | -5.77 Million USD | 1336.623% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 163.217% |
| Immix Biopharma, Inc. | -15.42 Million USD | 562.918% |
| Incyte Corporation | 597.59 Million USD | 88.051% |
| Innoviva, Inc. | 179.72 Million USD | 60.266% |
| IO Biotech, Inc. | -86.08 Million USD | 182.955% |
| Jaguar Health, Inc. | -41.3 Million USD | 272.906% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 146.676% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -36.921% |
| ContextLogic Inc. | -317 Million USD | 122.527% |
| MiMedx Group, Inc. | 67.43 Million USD | -5.888% |
| MEI Pharma, Inc. | 17.77 Million USD | -301.676% |
| NextCure, Inc. | -62.72 Million USD | 213.85% |
| Onconetix, Inc. | -37.4 Million USD | 290.886% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 280.881% |
| Opthea Limited | -220.24 Million USD | 132.423% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 239.584% |
| Vaxcyte, Inc. | -402.26 Million USD | 117.752% |
| PDS Biotechnology Corporation | -42.94 Million USD | 266.293% |
| Precigen, Inc. | -95.9 Million USD | 174.46% |
| Pharming Group N.V. | -10.54 Million USD | 777.0% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 135.423% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 390.959% |
| PureTech Health plc | -65.69 Million USD | 208.696% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 384.604% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 133.649% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 393.394% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 127.696% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 362.17% |
| Acelyrin, Inc. | -381.64 Million USD | 118.711% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 569435.605% |
| Summit Therapeutics Inc. | -614.92 Million USD | 111.613% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 309.407% |
| Senti Biosciences, Inc. | -92.91 Million USD | 176.852% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 168.205% |
| Elevation Oncology, Inc. | -45.7 Million USD | 256.245% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 303.216% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 646.288% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 1168.212% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 343.206% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 940.019% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 224.163% |
| Seer, Inc. | -86.27 Million USD | 182.768% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 206.59% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 208.584% |
| ESSA Pharma Inc. | -26.58 Million USD | 368.637% |
| GlycoMimetics, Inc. | -36.89 Million USD | 293.526% |
| GT Biopharma, Inc. | -7.59 Million USD | 1039.976% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 129.586% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 237.525% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 231.215% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 245.379% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 817.851% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 112.466% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 2090.245% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 239.861% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 129.076% |
| Aptose Biosciences Inc. | -51.2 Million USD | 239.454% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 172.646% |
| Soligenix, Inc. | -6.14 Million USD | 1262.891% |
| Century Therapeutics, Inc. | -136.67 Million USD | 152.249% |
| Kura Oncology, Inc. | -152.63 Million USD | 146.786% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 180.04% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 777.643% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -12528.433% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 12650.088% |
| Autolus Therapeutics plc | -208.38 Million USD | 134.269% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 199.321% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 200.869% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 429.564% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 131.703% |
| GRI Bio, Inc. | -13.03 Million USD | 647.749% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 1827.141% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 157.55% |
| IGM Biosciences, Inc. | -246.41 Million USD | 128.979% |
| INmune Bio, Inc. | -30 Million USD | 337.97% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 164.59% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 269.243% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 547.385% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 552.106% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 219.645% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 170.586% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 125.861% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 130.018% |
| Verastem, Inc. | -87.36 Million USD | 181.736% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 231.782% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 144.262% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 161.213% |
| Histogen Inc. | -10.62 Million USD | 772.347% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 599.834% |
| Surrozen, Inc. | -43.04 Million USD | 265.908% |
| Organovo Holdings, Inc. | -14.67 Million USD | 586.743% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 1503.766% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 236.438% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 382.666% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 365.09% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 954.484% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 147.265% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 245.955% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 340.235% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 785.468% |
| Apollomics, Inc. | -172.6 Million USD | 141.373% |
| Amarin Corporation plc | -59.11 Million USD | 220.805% |
| Mesoblast Limited | -87.95 Million USD | 181.188% |
| Turnstone Biologics Corp. | -55.2 Million USD | 229.366% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 148.591% |
| Synaptogenix, Inc. | -6.03 Million USD | 1282.578% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 540.585% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 191.528% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 1590.358% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 949.897% |
| Exelixis, Inc. | 207.76 Million USD | 65.629% |
| Better Therapeutics, Inc. | -39.76 Million USD | 279.603% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 149.608% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 113.509% |
| NLS Pharmaceutics AG | -12.17 Million USD | 686.673% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 1016.136% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 332.235% |
| Gritstone bio, Inc. | -138.49 Million USD | 151.563% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 210.773% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 1885.272% |
| Avid Bioservices, Inc. | -140.75 Million USD | 150.734% |
| Insmed Incorporated | -749.56 Million USD | 109.527% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 570.127% |
| MediWound Ltd. | -6.71 Million USD | 1163.282% |
| OmniAb, Inc. | -50.61 Million USD | 241.074% |
| Alector, Inc. | -130.39 Million USD | 154.766% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 162.792% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 237.732% |
| Zai Lab Limited | -334.62 Million USD | 121.341% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 122.041% |
| Aura Biosciences, Inc. | -76.4 Million USD | 193.459% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 130.435% |
| Immunic, Inc. | -93.61 Million USD | 176.283% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 152.549% |
| Veracyte, Inc. | -74.4 Million USD | 195.976% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 1030.357% |
| FibroGen, Inc. | -284.23 Million USD | 125.124% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 372.225% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 1119.867% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 479.181% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 82.786% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 416.604% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -44.933% |
| TG Therapeutics, Inc. | 12.67 Million USD | -463.526% |
| Galecto, Inc. | -38.34 Million USD | 286.211% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 478.512% |
| Fortrea Holdings Inc. | -3.4 Million USD | 2200.294% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 156.386% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 510.143% |
| XBiotech Inc. | -24.55 Million USD | 390.793% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 210.773% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 213.928% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 172.552% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 433.271% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 229.382% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 111.771% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 204.622% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 125525.932% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 131.522% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 420.691% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 132.502% |
| NexImmune, Inc. | -32.34 Million USD | 320.78% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 1450.78% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 608.405% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 98.194% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 394.827% |
| Scopus BioPharma Inc. | -11.6 Million USD | 715.082% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 161.14% |
| Ainos, Inc. | -13.77 Million USD | 618.57% |
| Pluri Inc. | -20.88 Million USD | 441.871% |
| Prothena Corporation plc | -147.02 Million USD | 148.569% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 162.711% |
| Celularity Inc. | -196.29 Million USD | 136.379% |
| Rallybio Corporation | -74.56 Million USD | 195.77% |
| Cue Biopharma, Inc. | -50.73 Million USD | 240.757% |
| MeiraGTx Holdings plc | -84.02 Million USD | 184.985% |
| Omeros Corporation | -117.81 Million USD | 160.613% |
| Humacyte, Inc. | -110.77 Million USD | 164.463% |
| Immunocore Holdings plc | -55.28 Million USD | 229.162% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 497.075% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 411.412% |
| Blueprint Medicines Corporation | -506.98 Million USD | 114.085% |
| CalciMedica, Inc. | -34.35 Million USD | 307.847% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 205.519% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 150.5% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 143.073% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 125.21% |
| Pulmatrix, Inc. | -14.12 Million USD | 605.701% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 302.898% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 186.413% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 114.84% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 168.093% |
| Cytokinetics, Incorporated | -526.24 Million USD | 113.57% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 298.004% |
| Nutriband Inc. | -5.48 Million USD | 1401.84% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 276.67% |
| Vor Biopharma Inc. | -117.86 Million USD | 160.587% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 98.358% |
| Evogene Ltd. | -23.87 Million USD | 399.049% |
| ProKidney Corp. | -35.46 Million USD | 301.336% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 159.626% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 1010.216% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 111.102% |
| CorMedix Inc. | -46.33 Million USD | 254.103% |
| BioLineRx Ltd. | -60.61 Million USD | 217.811% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 170.186% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 273.891% |
| Atai Life Sciences N.V. | -40.22 Million USD | 277.531% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 188.543% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 194.556% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 124.439% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 356.17% |
| MediciNova, Inc. | -8.57 Million USD | 933.108% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 157.926% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 952.47% |
| GeoVax Labs, Inc. | -25.96 Million USD | 375.005% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 129.849% |
| Biomea Fusion, Inc. | -117.25 Million USD | 160.901% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 111.396% |
| Mereo BioPharma Group plc | -29.46 Million USD | 342.347% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 146.624% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 134.109% |
| Absci Corporation | -110.56 Million USD | 164.586% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 336.849% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 170.817% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 130.267% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -407.029% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 137.007% |
| Allakos Inc. | -185.7 Million USD | 138.454% |
| Imunon, Inc. | -19.51 Million USD | 465.924% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 173.365% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 32.721% |
| BioAtla, Inc. | -123.46 Million USD | 157.84% |
| NLS Pharmaceutics AG | -12.17 Million USD | 686.673% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 544.147% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 121.82% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 293.266% |
| XOMA Corporation | -40.83 Million USD | 274.892% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 170.099% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 160.255% |
| aTyr Pharma, Inc. | -50.38 Million USD | 241.717% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 181.445% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 147.055% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 130.038% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 303.337% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 982.483% |
| Akari Therapeutics, Plc | -10 Million USD | 813.529% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 106167.583% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 74.641% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 1171.434% |
| UroGen Pharma Ltd. | -102.24 Million USD | 169.843% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 166.868% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 1018.199% |
| Orgenesis Inc. | -55.36 Million USD | 228.99% |
| Entera Bio Ltd. | -8.88 Million USD | 903.352% |
| GH Research PLC | -35.58 Million USD | 300.663% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 442.658% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 192.275% |
| Xencor, Inc. | -126.08 Million USD | 156.635% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 1996.326% |
| Replimune Group, Inc. | -215.79 Million USD | 133.092% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 435.786% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -2746.154% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 1171.434% |
| Portage Biotech Inc. | -75.33 Million USD | 194.785% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 952.47% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 173.881% |
| OncoCyte Corporation | -27.78 Million USD | 357.046% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 632.227% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 742.088% |
| Purple Biotech Ltd. | -19.88 Million USD | 459.205% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 1117.381% |
| scPharmaceuticals Inc. | -54.81 Million USD | 230.286% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 507.914% |
| HilleVax, Inc. | -123.56 Million USD | 157.791% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 806.54% |
| Tharimmune, Inc. | -9.31 Million USD | 866.276% |
| Genprex, Inc. | -30.86 Million USD | 331.396% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 130.268% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 337.29% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 4107.295% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 1448.372% |
| OKYO Pharma Limited | -16.82 Thousand USD | 424516.331% |
| Savara Inc. | -54.69 Million USD | 230.553% |
| Curis, Inc. | -47.41 Million USD | 250.613% |
| Daré Bioscience, Inc. | -30.16 Million USD | 336.76% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 562.348% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 1382.277% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 339.51% |
| BeiGene, Ltd. | -881.7 Million USD | 108.099% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 435.353% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 116.365% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 190.444% |
| Erasca, Inc. | -125.04 Million USD | 157.109% |
| bluebird bio, Inc. | -211.91 Million USD | 133.698% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 1528.058% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 57.404% |
| DBV Technologies S.A. | -72.72 Million USD | 198.19% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 1528.058% |
| Moderna, Inc. | -4.71 Billion USD | 101.515% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 277.827% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 1354.127% |
| Molecular Templates, Inc. | -8.12 Million USD | 979.0% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 218.252% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 164.103% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 152.759% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 249.022% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 150.492% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 137.113% |
| MacroGenics, Inc. | -9.05 Million USD | 888.364% |
| RenovoRx, Inc. | -10.23 Million USD | 797.909% |
| Adicet Bio, Inc. | -142.65 Million USD | 150.057% |
| Prime Medicine, Inc. | -198.13 Million USD | 136.041% |
| Aditxt, Inc. | -32.38 Million USD | 320.532% |
| Adagene Inc. | -18.94 Million USD | 476.906% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1076.651% |
| Quantum-Si incorporated | -95.96 Million USD | 174.416% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 159.994% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 589.856% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 46.036% |
| SciSparc Ltd. | -5.12 Million USD | 1494.182% |
| Vericel Corporation | -3.18 Million USD | 2344.186% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 59482.64% |
| Minerva Neurosciences, Inc. | -30 Million USD | 337.991% |
| Generation Bio Co. | -126.61 Million USD | 156.401% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 197.968% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 186.618% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 127.241% |
| Invivyd, Inc. | -198.64 Million USD | 135.949% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 120.882% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 922.073% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -213.119% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 823.212% |
| 2seventy bio, Inc. | -217.57 Million USD | 132.822% |
| ADMA Biologics, Inc. | -28.23 Million USD | 352.877% |
| Clene Inc. | -49.5 Million USD | 244.251% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 420.403% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 244.455% |
| GeoVax Labs, Inc. | -25.96 Million USD | 375.005% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 121.767% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 319.433% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -214.305% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 172.283% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 195.527% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 144.408% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 111.61% |
| Evaxion Biotech A/S | -22.12 Million USD | 422.757% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 188.449% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 135.693% |
| Trevena, Inc. | -40.28 Million USD | 277.244% |
| Surrozen, Inc. | -43.04 Million USD | 265.908% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 203.292% |
| Cingulate Inc. | -23.53 Million USD | 403.421% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 1133.131% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 279.152% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 1026.119% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 179.16% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 216.519% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 220.011% |
| Clearmind Medicine Inc. | -11.95 Million USD | 697.322% |
| Kronos Bio, Inc. | -112.67 Million USD | 163.378% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 203.198% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 2815696.377% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 183.136% |
| Statera Biopharma, Inc. | -174.4 Million USD | 140.944% |
| ImmunityBio, Inc. | -583.19 Million USD | 112.245% |
| Korro Bio, Inc. | -81.17 Million USD | 187.974% |
| Kineta, Inc. | -14.09 Million USD | 606.49% |
| BioVie Inc. | -32.12 Million USD | 322.319% |
| Codexis, Inc. | -76.24 Million USD | 193.665% |
| Celularity Inc. | -196.29 Million USD | 136.379% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 133.287% |
| Celcuity Inc. | -63.77 Million USD | 211.965% |
| Virax Biolabs Group Limited | -6.73 Million USD | 1160.512% |
| Cibus, Inc. | -267.62 Million USD | 126.683% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 277.082% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 299.408% |
| IN8bio, Inc. | -30 Million USD | 337.978% |
| Kodiak Sciences Inc. | -260.49 Million USD | 127.414% |
| Annexon, Inc. | -134.23 Million USD | 153.197% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 160.948% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 216.63% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 326.382% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 119.496% |
| Eyenovia, Inc. | -27.26 Million USD | 361.948% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -230.74% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 13447.664% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 193.464% |
| Arcellx, Inc. | -70.69 Million USD | 201.019% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 272.317% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 153.364% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 337.74% |
| Moolec Science SA | -51.78 Million USD | 237.887% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 236.354% |
| Geron Corporation | -184.12 Million USD | 138.783% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 270.129% |
| Royalty Pharma plc | 1.13 Billion USD | 93.707% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 152.524% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 903.099% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 436.154% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 141.597% |
| Humacyte, Inc. | -110.77 Million USD | 164.463% |
| Structure Therapeutics Inc. | -89.62 Million USD | 179.681% |
| 89bio, Inc. | -142.18 Million USD | 150.222% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 203.553% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 788.156% |
| Genelux Corporation | -28.29 Million USD | 352.359% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 345.691% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 140.318% |
| Notable Labs, Ltd. | -11.26 Million USD | 733.967% |
| Liquidia Corporation | -78.5 Million USD | 190.966% |
| Mustang Bio, Inc. | -51.6 Million USD | 238.386% |
| Immunovant, Inc. | -259.33 Million USD | 127.536% |
| Quantum-Si incorporated | -95.96 Million USD | 174.416% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 198.025% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 468.454% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 174.393% |
| Acasti Pharma Inc. | -12.85 Million USD | 655.59% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 417.973% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 547.385% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 139.152% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 1760.112% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 672.654% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 342.142% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 283.159% |
| PepGen Inc. | -78.62 Million USD | 190.822% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 339.88% |
| United Therapeutics Corporation | 984.8 Million USD | 92.749% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 420.8% |
| Solid Biosciences Inc. | -96.01 Million USD | 174.374% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 1590.358% |
| Immuneering Corporation | -53.47 Million USD | 233.547% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 1503.766% |
| Silo Pharma, Inc. | -3.7 Million USD | 2029.644% |
| Belite Bio, Inc | -31.63 Million USD | 325.752% |
| XOMA Corporation | -40.83 Million USD | 274.892% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 231.353% |
| Bionomics Limited | -15.49 Billion USD | 100.461% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 185.027% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 344.915% |
| uniQure N.V. | -308.47 Million USD | 123.149% |
| Cassava Sciences, Inc. | -97.21 Million USD | 173.454% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1076.651% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 157.855% |
| Forte Biosciences, Inc. | -31.47 Million USD | 326.871% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 970.673% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 345.665% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 13447.664% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 372.225% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 533.182% |
| Altimmune, Inc. | -88.44 Million USD | 180.738% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 147.109% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 344.915% |
| Compugen Ltd. | -18.75 Million USD | 480.772% |
| Peak Bio, Inc. | -1259.26 USD | 5670890.782% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 255.074% |
| Benitec Biopharma Inc. | -21.75 Million USD | 428.307% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 121.078% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 186.084% |
| Zura Bio Limited | -60.36 Million USD | 218.307% |
| PolyPid Ltd. | -23.86 Million USD | 399.225% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 553.916% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 186.084% |
| Instil Bio, Inc. | -156.08 Million USD | 145.75% |
| argenx SE | -295.05 Million USD | 124.202% |
| Immunome, Inc. | -106.8 Million USD | 166.86% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 268.047% |
| Verona Pharma plc | -54.36 Million USD | 231.343% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 171.469% |
| Shattuck Labs, Inc. | -87.29 Million USD | 181.8% |
| CervoMed Inc. | -2.17 Million USD | 3387.945% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 157.288% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 636.272% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 263.954% |
| Moolec Science SA | -51.78 Million USD | 237.887% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 413071.981% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 152.85% |
| AnaptysBio, Inc. | -163.61 Million USD | 143.644% |
| Design Therapeutics, Inc. | -66.86 Million USD | 206.802% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 187.712% |
| NeurAxis, Inc. | -14.62 Million USD | 588.217% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 288.506% |
| Lumos Pharma, Inc. | -34.03 Million USD | 309.82% |
| Achilles Therapeutics plc | -69.66 Million USD | 202.505% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 171.469% |
| 180 Life Sciences Corp. | -19.93 Million USD | 458.212% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -2273.379% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 2815696.377% |
| Nutriband Inc. | -5.48 Million USD | 1401.84% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 170.916% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 246.913% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 192.631% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 310.215% |
| MoonLake Immunotherapeutics | -36 Million USD | 298.321% |
| Palisade Bio, Inc. | -12.3 Million USD | 680.569% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 269.523% |
| Beam Therapeutics Inc. | -132.52 Million USD | 153.883% |
| Neurogene Inc. | -36.31 Million USD | 296.63% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 143.699% |
| AEON Biopharma, Inc. | -52.55 Million USD | 235.874% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 172.758% |
| Sesen Bio, Inc. | -19.88 Million USD | 459.133% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 199.757% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 670.646% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 116.082% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 164.007% |
| Athira Pharma, Inc. | -117.67 Million USD | 160.686% |
| Vaccinex, Inc. | -20.25 Million USD | 452.625% |
| HCW Biologics Inc. | -24.99 Million USD | 385.705% |
| XOMA Corporation | -40.83 Million USD | 274.892% |
| Nektar Therapeutics | -276.05 Million USD | 125.868% |
| Arvinas, Inc. | -367.3 Million USD | 119.442% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 106167.583% |
| Merus N.V. | -154.93 Million USD | 146.089% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 173.295% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 327.529% |
| Rezolute, Inc. | -68.45 Million USD | 204.311% |
| Clene Inc. | -49.5 Million USD | 244.251% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 562.996% |
| BeyondSpring Inc. | -21.02 Million USD | 439.627% |
| Synlogic, Inc. | -57.28 Million USD | 224.664% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 700.034% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 759.616% |
| Peak Bio, Inc. | -1259.26 USD | 5670890.782% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 291.099% |
| Krystal Biotech, Inc. | 10.93 Million USD | -553.22% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 149.903% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 121.965% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 1646.017% |
| MannKind Corporation | -11.93 Million USD | 698.174% |
| Ikena Oncology, Inc. | -68.16 Million USD | 204.759% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 439.805% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 176.84% |
| Gossamer Bio, Inc. | -179.81 Million USD | 139.713% |
| CohBar, Inc. | -11.96 Million USD | 696.968% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 376.912% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 336.849% |
| Legend Biotech Corporation | -518.25 Million USD | 113.779% |
| Mural Oncology plc | -207.44 Million USD | 134.423% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 157.535% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 490.438% |
| Disc Medicine, Inc. | -76.42 Million USD | 193.433% |
| Champions Oncology, Inc. | -7.27 Million USD | 1081.446% |
| REGENXBIO Inc. | -263.49 Million USD | 127.101% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 772.849% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 250.321% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 288.003% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 171.294% |
| Vaxart, Inc. | -82.46 Million USD | 186.594% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -21295.421% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 290.211% |
| Cellectis S.A. | -101.05 Million USD | 170.662% |
| Longeveron Inc. | -21.41 Million USD | 433.489% |
| Repare Therapeutics Inc. | -93.79 Million USD | 176.133% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 113.323% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 200.339% |
| Revolution Medicines, Inc. | -436.36 Million USD | 116.365% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 1186.745% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 331.67% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 202.996% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 210.316% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 827.856% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 98.027% |
| Denali Therapeutics Inc. | -145.22 Million USD | 149.172% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 59482.64% |
| Veru Inc. | -93.15 Million USD | 176.659% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 364.198% |
| Cingulate Inc. | -23.53 Million USD | 403.421% |
| Passage Bio, Inc. | -102.06 Million USD | 169.967% |
| Context Therapeutics Inc. | -23.96 Million USD | 397.986% |
| Exicure, Inc. | -16.91 Million USD | 522.195% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 137.8% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 289.095% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 1197.379% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 138.667% |
| Nuvalent, Inc. | -126.21 Million USD | 156.576% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 779.083% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 182.195% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 333.794% |
| OmniAb, Inc. | -50.61 Million USD | 241.074% |
| Anew Medical, Inc. | 1.34 Million USD | -5204.857% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 545.061% |
| Lipocine Inc. | -16.35 Million USD | 536.703% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 207.555% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 212.148% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 269.243% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 248.873% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 460.093% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 113.188% |
| Ocugen, Inc. | -63.07 Million USD | 213.209% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 174.594% |
| Q32 Bio Inc. | -112.96 Million USD | 163.217% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 515.368% |
| Alumis Inc. Common Stock | -154.99 Million USD | 146.073% |
| Equillium, Inc. | -13.33 Million USD | 635.508% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 218.295% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 993.984% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 478.808% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 220.866% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 162.352% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 488.563% |
| Dominari Holdings Inc. | -22.88 Million USD | 412.079% |
| Edesa Biotech, Inc. | -8.37 Million USD | 952.716% |
| vTv Therapeutics Inc. | -20.25 Million USD | 452.642% |
| Bio-Techne Corporation | 168.1 Million USD | 57.521% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 120.282% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 44.58% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 158.614% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 288.223% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 163.396% |
| Nkarta, Inc. | -117.5 Million USD | 160.774% |
| BioCardia, Inc. | -11.57 Million USD | 717.146% |
| Iterum Therapeutics plc | -38.37 Million USD | 286.104% |